Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Francesca Bianchi in
Google Scholar
PubMed
Search for other papers by Federica Brozzi in
Google Scholar
PubMed
Search for other papers by Pierina Santini in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Valeria Bottici in
Google Scholar
PubMed
Search for other papers by David Viola in
Google Scholar
PubMed
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
the potential secondary side effects, particularly in patients with low-risk (LR) and intermediate-risk (IR) DTC, even if these effects are negligible for RAI activities < 100 mCi [ 5 - 7 ]. Nowadays, there is a general agreement that LR DTC should not
Search for other papers by Syed Ali Imran in
Google Scholar
PubMed
Search for other papers by Karen Chu in
Google Scholar
PubMed
Search for other papers by Murali Rajaraman in
Google Scholar
PubMed
Search for other papers by Drew Rajaraman in
Google Scholar
PubMed
Search for other papers by Sunita Ghosh in
Google Scholar
PubMed
Search for other papers by Sarah De Brabandere in
Google Scholar
PubMed
Search for other papers by Stephanie M. Kaiser in
Google Scholar
PubMed
Search for other papers by Stan Van Uum in
Google Scholar
PubMed
detection of small, subclinical tumours which contribute to the rising incidence of TC [ 11 ]. Regardless, the outlook of TC is generally excellent, with an overall 5-year survival of 97.9%, and that of low-risk TC (stage I and II) is almost 100% [ 12
Search for other papers by Aglaia Kyrilli in
Google Scholar
PubMed
Search for other papers by Nunzia Tacelli in
Google Scholar
PubMed
Search for other papers by Lucia Russo in
Google Scholar
PubMed
Search for other papers by Laetitia Lebrun in
Google Scholar
PubMed
Search for other papers by Isabelle Salmon in
Google Scholar
PubMed
Search for other papers by Gilles Russ in
Google Scholar
PubMed
Search for other papers by Rodrigo Moreno-Reyes in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
(US), the first-line tool to stratify malignancy risk of thyroid nodules, does not, unlike scintigraphy, evaluate the nodule’s functional characteristics. The utility to effectively diagnose AFTN relies on the generally admitted assumption that AFTN
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by Cláudia C.D. Nakabashi in
Google Scholar
PubMed
Search for other papers by Teresa S. Kasamatsu in
Google Scholar
PubMed
Search for other papers by Felipe Crispim in
Google Scholar
PubMed
Search for other papers by Claudia A. Yamazaki in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Cléber P. Camacho in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Danielle M. Andreoni in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Rosalia P. Padovani in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Elza S. Ikejiri in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Maria C.O.M. Mamone in
Google Scholar
PubMed
Search for other papers by Flávia C. Aldighieri in
Google Scholar
PubMed
Search for other papers by Jairo Wagner in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Jairo T. Hidal in
Google Scholar
PubMed
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by José G.H. Vieira in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by Rosa P.M. Biscolla in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by Rui M.B. Maciel in
Google Scholar
PubMed
a nonsignificant risk of recurrence from undergoing unnecessary investigations and identify those individuals with a higher risk who merit closer follow-up [ 6 , 7 ]. The measurement of serum thyroglobulin (Tg) levels is one of the most important
Search for other papers by Furio Pacini in
Google Scholar
PubMed
therapy by cleaning persistent microscopic foci of cancer, which can be present in the thyroid remnant. While the first aim - remnant ablation - is related to follow-up in any patient regardless of his specific risk, the second one - adjuvant therapy - is
Search for other papers by David J. Stott in
Google Scholar
PubMed
Search for other papers by Douglas C. Bauer in
Google Scholar
PubMed
Search for other papers by Ian Ford in
Google Scholar
PubMed
Search for other papers by Patricia Kearney in
Google Scholar
PubMed
Search for other papers by Jacobijn Gussekloo in
Google Scholar
PubMed
Search for other papers by Terence J. Quinn in
Google Scholar
PubMed
Search for other papers by Nicolas Rodondi in
Google Scholar
PubMed
Search for other papers by Jan Smit in
Google Scholar
PubMed
Search for other papers by Rudi Westerdorp in
Google Scholar
PubMed
useful background and guidance, we suggest that the approach recommended there carries potential risks, with the likely outcome of an increase in the proportion of ‘younger' elderly patients treated for SCH and the withholding of thyroxine treatment in
Guided Therapeutics (GTx) Program, Techna Institute, University Health Network, Toronto, Ontario, Canada
Search for other papers by Axel Sahovaler in
Google Scholar
PubMed
Unit of Otorhinolaryngology – Head and Neck Surgery, Department of Medical and Surgical Specialties, Radiologic Sciences, and Public Health, University of Brescia, Brescia, Italy
Section of Otorhinolaryngology – Head and Neck Surgery, Department of Neurosciences, University of Padua, Padua, Italy
Search for other papers by Marco Ferrari in
Google Scholar
PubMed
Search for other papers by Jonathan Athayde in
Google Scholar
PubMed
Search for other papers by Adrian Mendez in
Google Scholar
PubMed
Search for other papers by Kevin Fung in
Google Scholar
PubMed
Search for other papers by John Yoo in
Google Scholar
PubMed
Search for other papers by Anthony C. Nichols in
Google Scholar
PubMed
Search for other papers by S. Danielle MacNeil in
Google Scholar
PubMed
Dear Editor, The recently published “Systematic Review of Recurrence Rate after Hemithyroidectomy for Low-Risk Well-Differentiated Thyroid Cancer” (WDTC) by Chan et al. [ 1 ] aimed to focus on tumors between 1 and 4 cm, which represent the
Search for other papers by Chitra Choudhary in
Google Scholar
PubMed
Search for other papers by Leonard Wartofsky in
Google Scholar
PubMed
Search for other papers by Eshetu Tefera in
Google Scholar
PubMed
Search for other papers by Kenneth D. Burman in
Google Scholar
PubMed
ultrasonography, with occasional imaging by MRI, FDG-PET or 131 I scanning depending on the clinical context. Neck ultrasound is recommended at 6-12 months after surgery and then less frequently depending on the risks for loco-regional recurrence [ 1 , 2
Search for other papers by Samuel Chan in
Google Scholar
PubMed
Search for other papers by Katarina Karamali in
Google Scholar
PubMed
Search for other papers by Anna Kolodziejczyk in
Google Scholar
PubMed
Search for other papers by Georgio Oikonomou in
Google Scholar
PubMed
Search for other papers by John Watkinson in
Google Scholar
PubMed
Search for other papers by Vinidh Paleri in
Google Scholar
PubMed
Search for other papers by Iain J. Nixon in
Google Scholar
PubMed
Search for other papers by Dae Kim in
Google Scholar
PubMed
data, we have shown that the pooled recurrence rate after HT in all included studies, as well as a subset of these studies that define a low-risk cohort of patients, is approximately 9% in both groups. We found this rate to be marginally but
Search for other papers by Leonidas H. Duntas in
Google Scholar
PubMed
Search for other papers by Georg Brabant in
Google Scholar
PubMed
Search for other papers by Fabio Monzani in
Google Scholar
PubMed
Royal Victoria Infirmary, Newcastle upon Tyne, UK
Search for other papers by Simon H.S. Pearce in
Google Scholar
PubMed
Search for other papers by Robin Patrick Peeters in
Google Scholar
PubMed
Queen Elizabeth Hospital, Gateshead, UK
Search for other papers by Salman Razvi in
Google Scholar
PubMed
Search for other papers by Jean-Louis Wemeau in
Google Scholar
PubMed
We appreciate the interest of Stott et al. [ 1 ] in the Management of Subclinical Hypothyroidism ETA Guidelines 2013 [ 2 ]. We are, however, somewhat puzzled by the authors' statement that the guidelines ‘risk doing more harm than good